Search General Info
Search Education
Search Partnering Companies
photo
Speaker

Mark Theeuwes

CEO, RECEPTOR LIFE SCIENCES
Seattle, Washington, United States
Mark is a healthcare executive with more than 20 years of experience. He has a wide range of focus both on the clinical and commercial sides of the business within the rare diseases, Neurology, urology, pain, primary care, infectious disease and dental industries. Most recently, Mark served as Executive Vice President and Chief Operating Officer of Engage Therapeutics. Engage Therapeutics was in the process of developing Staccato® Alprazolam and if approved will be the first and only drug-device-combination for the rapid termination of an active epileptic seizure. Engage was sold to UCB in 2020 in a deal valued at $270 million following the successful completion of its randomized, phase 2b clinical study.
Speaking In
[On Demand]
Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug-delivery…